KariyerYatırımcı ilişkileriHakkımızda
Login
  1. Siemens Healthineers Türkiye
  2. Tıbbi Görüntüleme
  3. Moleküler Görüntüleme
  4. MI Trends and Innovations
  5. The Value of Molecular Imaging for Prostate Cancer
Clinical molecular imaging prostate image

Prostat kanseri için değerli olan moleküler görüntülemeÖdün vermeden moleküler görüntüleme

Prostat kanseri gerçekleri ve rakamları

Teşhis zorlukları

prostate cancer facts and figures
Moleküler görüntüleme teknikleri, anatomik modalitelerde eksik olan prostat kanserinin biyolojik karakterizasyon bilgisini müdahalesiz olarak verir. Moleküler Görüntüleme modalitesi, hücresel metabolizmadaki fizyolojik anormallikleri ve prostat kanserinde meydana gelen çeşitli hücresel yüzey proteinlerinin ekspresyonunu değerlendirerek hastalığın daha doğru bir şekilde tanısını sağlar.

Klinik resim galerisi

PET/CT in prostate cancer
Data courtesy of Prof. Dr. Drzezga, Clinic for Nuclear Medicine, University Hospital Cologne, Cologne, Germany.

Vaka çalışmaları

A 68Ga PSMA study, performed on Biograph Vision, aides in the visualization of bladder invasion and pelvic lymph node metastases.

Detection of Bladder Invasion and Pelvic Lymph Node Metastases in a Patient with Primary Prostate Cancer

A 62-year-old man with primary prostate cancer, diagnosed on clinical examination and transrectal ultrasound, underwent 68Ga PSMA5 PET/CT for initial staging. The PET/CT study was performed on Biograph Vision™.

A 68Ga PSMA study, performed on Biograph Vision, aides in the visualization of a solitary lymph node metastasis in a patient with primary prostate cancer.

Detection of Solitary Pelvic Lymph Node Metastasis in a Patient with Primary Prostate Cancer

A 78-year-old male with a medical history of lower urinary tract symptoms, referred for primary staging of his newly-diagnosed Gleason 3+4 prostate cancer, underwent a 68Ga PSMA5 PET/CT for initial staging on Biograph Vision™.

A xSPECT Quant image quantifies a rib lesion on a SPECT/CT scan.

Differentiation of a rib benign lesion from a metastasis using xSPECT Quant

A 58-year-old patient with prostatic hypertrophy underwent a prostatectomy, which led to an incidental discovery of adenocarcinoma of the prostate. After initial planar acquisitions were conducted, a subsequent SPECT/CT examination using xSPECT Bone™ and xSPECT Quant™ was administered for the thorax.

1
Siegel, R., Miller, K. & Jemal, A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 67, 7–30 (2017).
2
Torre, LA., et al. Global cancer statistics, 2012, CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262.
3
The tracer mentioned is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries.
4
Please see indication and important safety information at www.mayoclinic.org
5
68Ga PSMA referenced herein is (are) not currently recognized by the US FDA as being safe and effective, and Siemens does not make any claims regarding its use.
Image data courtesy of WVU Medical Center, Morgantown, West Virginia, USA.